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Abstract
Background and Objectives: Five-tumour necrosis factor (TNF)-blockers (infliximab, etanercept, adalimumab, certolizumab
pegol and golimumab) are available for treatment of rheumatoid arthritis. Only few clinical trials compare one TNF-blocker
to another. Hence, a systematic review is required to indirectly compare the substances. The aim of our study is to estimate
the efficacy and the safety of TNF-blockers in the treatment of rheumatoid arthritis (RA) and indirectly compare all five
currently available blockers by combining the results from included randomized clinical trials (RCT).
Methods: A systematic literature review was conducted using databases including: MEDLINE, SCOPUS (including EMBASE),
Cochrane library and electronic search alerts. Only articles reporting double-blind RCTs of TNF-blockers vs. placebo, with or
without concomitant methotrexate (MTX), in treatment of RA were selected. Data collected were information of patients,
interventions, controls, outcomes, study methods and eventual sources of bias.
Results: Forty-one articles reporting on 26 RCTs were included in the systematic review and meta-analysis. Five RCTs studied
infliximab, seven etanercept, eight adalimumab, three golimumab and three certolizumab. TNF-blockers were more
efficacious than placebo at all time points but were comparable to MTX. TNF-blocker and MTX combination was superior to
either MTX or TNF-blocker alone. Increasing doses did not improve the efficacy. TNF-blockers were relatively safe compared
to either MTX or placebo.
Conclusions: No single substance clearly rose above others in efficacy, but the results of the safety analyses suggest that
etanercept might be the safest alternative. Interestingly, MTX performs nearly identically considering both efficacy and
safety aspects with a margin of costs.
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Introduction
Rheumatoid arthritis (RA) is an inflammatory autoimmune
disease with a prevalence of 0.5–1.0 per cent in Northern Europe
[1]. A recent epidemiological study from Sweden reported that
0.77% of the population have been diagnosed with RA while a
survey from UK found the prevalence to be 0.82% [2,3]. RA is
usually diagnosed before the age of 60 and is more common in
women than men. Both genetic and environmental factors play a
role [4]. Symptoms include joint destruction, pain and impaired
movement.
Since the discovery of the role of tumour necrosis factor (TNF)
in chronic inflammation in RA, five drugs based on blocking TNF
have entered clinical use. Infliximab, adalimumab, golimumab
and certolizumab pegol (certolizumab) are monoclonal antibodies
targeted against TNF whereas etanercept is a soluble TNF-
receptor [5]. However, only few clinical trials compared one TNF-
blocker to other TNF-blockers. Previous systematic reviews and
meta-analyses have studied the subject in various settings and
comparisons [6–14]. These studies concluded that while TNF-
blockers are efficacious but it may still be beneficial to use them in
combination therapies. Only few differences in efficacy and safety
between individual substances were discovered. However, more
randomized clinical trials have been published lately with
additional data available to systematic reviews and most
importantly, two new substances, certolizumab and golimumab,
have been introduced to clinical use.
The purpose of this systematic review and meta-analysis is to
study the efficacy and safety of all five currently available TNF-
blockers in the treatment of RA compared to either methotrexate
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(MTX) and placebo or placebo alone and to perform an indirect
comparison between individual substances in different drug
combinations and doses and at different time points. We test the
assumption that it is more efficacious and comparatively safer to
use MTX in combination with a TNF-blocker in the treatment of
RA compared to TNF-blocker monotherapy. We study if high
doses of TNF-blockers differ from regular doses in efficacy and
safety. Primary efficacy endpoint is the risk ratio between
intervention and control group in American College of Rheuma-
tology (ACR) 50% improvement at 6 months [15,16]. Secondary
efficacy endpoints include risk ratios in ACR 20%, 50% and 70%
improvements at 3, 6 and 12 months in several comparisons.
Primary safety endpoint is the risk ratio between intervention and
control group in the number of discontinuations due to adverse
events. Secondary safety endpoints include risk ratios in the
number of adverse events, serious adverse events, infections,
serious infections and injection site reactions.
Methods
Study selection criteria
We performed a search for randomized clinical trials of five
TNF-blockers in treatment of RA. Systematic review was
conducted in accordance to methods and recommendations from
the Cochrane handbook [17].
According to inclusion criteria patients had to be at least 16
years of age; be diagnosed with RA using ACR 1987 criteria; and
be randomized either to intervention or control group. Studies
were to have one (or more) of the TNF-blockers as intervention
and either placebo or combination of placebo and methotrexate as
control. The TNF-blocker had to be delivered through the same
route as the commercial drug and be within the dose range
recommended for the commercially available products. Efficacy
was measured in terms of ACR 20%, 50% and 70% improve-
ments and thus, at least one of these had to be reported at some
time point. Information regarding safety had to be reported.
Previously published systematic reviews were searched for, but
excluded from the systematic review due to the inclusion criteria.
The protocol of the study was not published online.
Search strategy
Search strategy was designed and performed by a librarian by
our request. We used the search terms rheumatoid arthritis, anti-
TNF, infliximab, etanercept, adalimumab, golimumab, certolizu-
mab, randomized clinical trials and systematic review. Variations
in spelling were taken into account. References from (OvidH)
Medline, Cochrane library (Cochrane Central register of Con-
trolled Trials, Cochrane Database for Systematic Reviews, Health
Technology Assessment, Database of Abstracts of Reviews of
Effects, NHS Economic Evaluation, Cochrane Methodology
Register), SCOPUS (including Embase), ISI web of knowledge
and several other databases were extracted and imported to
reference management software (RefWorks). Clinical trial register
(clinicaltrials.gov) was hand searched for unpublished trials.
Duplicate entries were removed using an automated feature.
There were no restrictions on study language. For search strategy,
see table S1.
Study selection
References were evaluated by two individual investigators (KA,
LV) using pre-defined inclusion and exclusion criteria. Decision
for inclusion was made on consensus. A third investigator (YTK)
made the final decision in case of disagreement. Evaluation was
based on title and abstract whenever available. Full text articles
from potentially relevant references were obtained in electronic or
printed format and re-evaluated for inclusion by the same
investigators as before. The acronym PICOS (patients, interven-
tions, comparators, outcomes and settings) was used to assess if the
references fully complied with the inclusion and exclusion criteria.
As full-text article was required for the systematic review and
meta-analysis, references whose full-texts we could not acquire
either electronically or as printed copies from the University of
Helsinki medical library were excluded. Multiple reports from a
single study were considered as one study.
Evaluation for bias
As instructed in the Cochrane handbook for systematic reviews
of interventions, the investigators performed an evaluation of bias
rather than of methodological quality. Studies included were
evaluated for an eventual bias using methods described in the
Cochrane handbook. The study was to be considered ‘‘possibly
biased’’ in case a possible source of bias was found in any of the
seven dimensions evaluated. The following dimensions were
considered in the bias assessment tool: Allocation sequence
generation, allocation concealment, blinding of participants,
personnel and outcome, incomplete outcome data, selective
outcome reporting and other sources of bias. Evaluation was
done by two independent assessors (KA, LV) to improve the
validity. The effect of possible bias on results was studied by
performing all meta-analysis twice with possibly biased RCTs
included and excluded.
Data extraction
Data on study design, patient status and background, efficacy
and safety were extracted from the publications using an Excel
data extraction form by two independent researchers (KA, LV) to
improve validity.
Meta-analyses
Data were analyzed using the intention to treat results from the
included studies. Meta-analyses were performed using Cochrane
Collaboration Review Manager 5.0 software. Sensitivity analyses
were employed to account for the possible bias. In some settings
several time points were combined to increase the power. Efficacy
and safety were analyzed using dichotomous data to obtain risk
ratios. Dichotomous efficacy data included ACR 20%, 50% and
70% improvements whereas dichotomous safety data was
composed of the proportion of patients who experienced an
adverse outcome or discontinued the treatment due to adverse
events. The efficacy and safety of TNF-blockers was analyzed in
six different main comparisons. Random effects model was used to
account for the diversity of the studies. Heterogeneity was
evaluated via subgroup analysis using Chi square and I2-statistics.
Results
Search results
5308 references were identified from electronic databases by a
systematic literature search performed 5.-26.2.2010. 1613 were
identified as duplicates by an automated feature in RefWorks.
Additionally, 146 references were added via ‘‘search alerts’’, which
extended time coverage of the search to 30.6.2010. No additional
references were identified from alternative sources including
clinical trial registers.
Study selection
After removing duplicate entries, 3841 references were
evaluated for inclusion based on title and/or abstract. Seventy
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six potentially relevant references were included in the next stage,
where the publication was to be re-evaluated based on full text
(figure 1). Full text was unavailable for 12 studies most of which
were conference abstracts identified from ISI Web of Knowledge
[18–29]. Patients, interventions, controls, outcomes or design of
the studies did not meet the inclusion criteria of the systematic
review in 17 publications [30–46]. Five review articles, one letter
to the editor [47] and one erratum [48] were excluded. Several of
the remaining 40 publications were reporting on a single study
and were thus merged into one (table S2). Publications included
in the systematic review and meta-analysis are listed in the
bibliography with numbers 49–88. From the 26 clinical trials
included in the systematic review, 8 used adalimumab, 7
etanercept , 5 infliximab, 3 golimumab and 3 certolizumab for
intervention. The included trials have 9862 patients of which
6780 and 3082 were in intervention and control groups,
respectively (table S2).
Evaluation for bias
A potential source of bias was discovered in five trials included
in the systematic review (table 1). In many clinical trials there was
an early escape route for patients with insufficient treatment
response to avoid rapid disease progression. In some studies this
was implemented by considering all patients failing to meet a pre-
defined treatment response criteria (e.g. ACR 20% improvement)
as ‘‘non-responders’’ before the actual efficacy assessment. While
this may be for the best interest of the study subjects, it may
introduce a bias to the evaluation of the efficacy results. Another
bias was caused by switching the control group to active
medication.
Figure 1. Flowchart of the selection process of the RCTs for the systematic review and meta-analysis.
doi:10.1371/journal.pone.0030275.g001
A Systematic Review of TNF-Blockers in RA
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30275
Efficacy
TNF-blocker vs. control. The primary efficacy endpoint of
our study was the risk ratio of 50% improvements in the ACR-
treatment response criteria at six months between intervention and
control group. Fourteen trials were included and of them 2 used
infliximab, 2 etanercept, 5 adalimumab, 2 golimumab and 3
certolizumab for intervention. As a group, TNF-blockers reached
a risk ratio of 4.07 (95% CI 2.70–6.13) regarding the achievement
of the efficacy endpoint compared to controls. For infliximab,
etanercept, adalimumab, golimumab and certolizumab the
corresponding figures were 3.08 (0.91–10.43), 8.61 (3.55–20.86),
4.34 (3.30–5.70), 1.56 (0.93–2.60) and 5.95 (3.97–8.92),
respectively (figure 2). These results suggest that infliximab and
golimumab do not differ significantly from the control. In this
comparison golimumab appears to be inferior in efficacy
compared to etanercept, adalimumab and certolizumab even
after accounting for the possible bias. TNF-blockers as a group
were found to be significantly more efficacious than control at all
time points using ACR 20, 50 or 70 as outcome measures. The risk
ratios observed at 12 months were significantly lower than those at
three or six months.
We found some evidence that the duration of RA predicts the
efficacy of TNF-blocker treatment. Patients on either infliximab or
adalimumab with disease duration more than 2 years were more
likely to reach ACR 20, 50 and 70 at 12 months compared to
controls than patients with disease duration less than two years
(table 2).
TNF-blocker + MTX vs. MTX. Patients on combination
therapy had significantly higher ACR outcomes than ones treated
with MTX alone at all time points (table 3). A statistically
significant difference was revealed between ACR 20 risk ratios of
certolizumab (CI 95% 5.08, 3.46–7.48) and golimumab (1.61,
0.94–2.76). However, all certolizumab studies in this comparison
were potentially biased. In a subanalysis of trials with patients who
Table 1. The results of an assessment for bias in accordance to a tool by Cochrane Collaboration.*
Study
Sequence
Generation
Allocation
Concealment Blinding
Incomplete
Outcome Data
Selective
Outcome
Reporting Other Potential Threats To Validity
Infliximab
Abe 2006 Unclear Unclear Yes Yes Yes Yes
Maini 1999 Yes Yes Yes Yes Yes Yes
Quinn 2005 Unclear Unclear Yes Unclear Yes Unclear
St. Clair 2004 Yes Yes Yes Unclear Yes Yes
Schiff 2008 Unclear Unclear Yes Yes Yes Yes until 6 mo/No
Etanercept
Bathon 2000 Unclear Unclear Yes Unclear Yes Yes
Emery 2008 Yes Yes Yes Unclear Yes Yes
Keystone 2004 Unclear Unclear Yes Yes Yes Yes until 8 wk/No
Klareskog 2004 Yes Yes Yes Yes Yes Yes
Lan 2004 Unclear Unclear Yes Yes Yes Yes
Moreland 1999 Unclear Yes Yes Yes Yes Yes
Weinblatt 1999 Unclear Yes Yes Yes Yes Yes
Adalimumab
Breedveld 2006 Unclear Unclear Yes Yes Yes Yes
Chen 2009 Unclear Unclear Yes Yes Yes Yes
Keystone 2004 Unclear Unclear Yes Yes Yes Yes
Kim 2007 Unclear Unclear Yes Yes Yes Yes
Miyasaka 2008 Unclear Unclear Yes Yes Yes No
Van de Putte 2003 Unclear Unclear Yes Yes Yes Yes
Van de Putte 2004 Yes Yes Yes Yes Yes Yes
Weinblatt 2003 Unclear Unclear Yes Yes Yes Yes
Golimumab
Emery 2009 Yes Yes Yes Yes Yes Yes
Kay 2008 Unclear Unclear Yes Yes Yes Yes
Keystone 2009 Yes Yes Yes Unclear Yes Yes until 16 wk/No
Certolizumab
Fleischmann 2008 Yes Yes Yes Yes Yes Yes
Keystone 2008 Unclear Unclear Yes Yes Yes No
Smolen 2009 Unclear Unclear Yes Yes Yes No
*Yes = free of bias, No= possible source of bias, Unclear = not enough information to make the decision.
doi:10.1371/journal.pone.0030275.t001
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had previously used MTX, the results were similar. In comparison
to MTX, golimumab combination therapy was still inferior in
ACR 20 efficacy at 6 months to certolizumab combination
therapy, with risk ratios of 2.14 (1.59–2.89) and 5.08 (3.46–7.48),
respectively. At six months patients previously naı¨ve to MTX are
statistically significantly less likely to reach either ACR 20, 50 or
70 treatment responses compared to patients who had already
been previously treated with MTX. The combination of TNF-
blocker and MTX was superior in efficacy to monotherapy with a
TNF-blocker at almost all time points (table 4).
TNF-blocker monotherapy vs. MTX. There are no trials
comparing monotherapy of infliximab to MTX, but combined
results with the remaining four other TNF-blockers show that
while the risk ratios favour the TNF-blocker, the results do not
Figure 2. Forest plot of the ACR 50 response at 6 months.
doi:10.1371/journal.pone.0030275.g002
A Systematic Review of TNF-Blockers in RA
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30275
reach statistical significance at any time point using ACR 20, 50 or
70 as outcome measures. Stratifying RTCs by previous exposure
to MTX does not show any statistically significant differences in
the treatment response to TNF-blocker monotherapy between
these two groups.
TNF-blocker monotherapy vs. placebo. All four TNF-
blockers were more efficacious than placebo with the estimates of
risk ratios ranging from 2.74 (CI 95% 1.76–4.26) – 12.31 (1.64–
92.41). There were no statistically significant differences in efficacy
between individual substances in this comparison or, alternatively,
the meta-analysis was underpowered to reveal them.
High doses of TNF-blockers vs. normal doses. The final
meta-analysis compared higher than regular doses of TNF-
blockers to normal doses (table 5). Both patients using high and
normal doses had to be on concomitant MTX or on TNF-blocker
monotherapy. Increasing the dose of TNF-blocker provided no
additional efficacy compared to regular doses except 12 months
with possibly biased results excluded.
Sensitivity analyses
The sensitivity analyses based on the results of the bias
assessments did not reveal any statistically significant bias on the
efficacy results. Occasionally, however, the statistical significance
between intervention and control groups disappeared due to
reduced number of studies. In the sensitivity analyses, the estimate
of the risk ratio decreased, increased or remained the same in
52%, 45% and 3% of cases, respectively. In some cases there were
no clearly unbiased RCTs in a comparison, thus making it
impossible to perform the sensitivity analysis. Significant hetero-
geneity was present in the first analysis comparing any
intervention to any control. Heterogeneity diminished as the
comparisons were stratified into smaller comparisons.
Table 2. Meta-analysis of the efficacy of TNF-blockers compared to control(RR, 95% CI).
ACR 20 3kk ACR 50 3kk ACR 70 3kk ACR 20 6kk
ACR 50
6kk
ACR 70
6kk
ACR 20
12kk
ACR 50
12kk
ACR 70
12kk
TNF-blocker vs. control (including all combinations and doses of tnf-blocker vs. any control)
Infliximab 2.51 (1.51–
4.15) 2
4.44 (1.77–
11.16) 2
12.92 (1.81–
92.02) 2
1.89 (1.00–
3.56) 2
3.08 (0.91–
10.43) 2
5.17 (0.61–
43.54) 2
1.70 (0.86–
3.38) 3
2.24 (1.11–
4.50) 3
2.71 (1.09–
6.70) 3
Etanercept 2.07 (1.25–
3.42) 5
3.96 (1.55–
10.14) 5
3.14 (1.93–
5.10) 5
3.72 (1.91–
7.24) 2
8.61 (3.55–
20.86) 2
11.40 (2.21–
58.65) 2
1.15 (1.03–
1.29) 3
1.41 (1.26–
1.57) 2
1.74 (1.44–
2.09) 2
Adalimumab 3.40 (1.79–
6.48) 3
5.42 (1.75–
16.80) 3
8.25 (2.33–
29.19) 3
2.53 (1.87–
3.43) 5
4.34 (3.30–
5.70) 5
5.44 (3.03–
9.76) 5
1.56 (0.62–
3.90) 2
2.18 (0.54–
8.83) 2
2.47 (0.61–
10.02) 2
Golimumab 1.56 (1.24–
1.97) 2
3.03 (1.82–
5.04) 2
2.91 (1.21–
7.00) 2
1.42 (0.95–
2.12) 2
1.56 (0.93–
2.60) 2
1.72 (0.74–
3.99) 2
n/a n/a n/a
Certolizumab n/a n/a n/a 3.67 (1.35–
9.96) 3
5.95 (3.97–
8.92) 3
8.12 (3.96–
16.63) 3
n/a n/a n/a
Combined 2.24 (1.63–
3.08) 12
4.16 (2.44–
7.09) 12
3.59 (2.42–
5.33) 12
2.50 (1.90–
3.30) 14
4.07 (2.70–
6.13) 14
4.94 (2.80–
8,71) 14
1.35 (1.14–
1.59) 8
1.76 (1.36–
2.27) 7
1.94 (1.46–
2.57) 7
TNF-blocker vs. control (early RA, disease duration #2 years)
Infliximab 3.00 (0.79–
11.44) 1
13.00 (0.83–
203.83) 1
13.00 (0.83–
203.83) 1
n/a n/a n/a 1.20 (1.07–
1.36) 2
1.52 (1.26–
1.82) 2
1.68 (1.32–
2.14) 2
Etanercept n/a n/a n/a n/a n/a n/a 1.20 (1.04–
1.38) 2
1.44 (1.24–
1.68) 1
1.71 (1.35–
2.16) 1
Adalimumab n/a n/a n/a n/a n/a n/a 1.01 (0.90–
1.13) 1
1.12 (0.96–
1.31) 1
1.28 (1.02–
1.60) 1
Golimumab n/a n/a n/a n/a n/a n/a n/a n/a n/a
Certolizumab n/a n/a n/a n/a n/a n/a n/a n/a n/a
Combined 3.00 (0.79–
11.44) 1
13.00 (0.83–
203.83) 1
13.00 (0.83–
203.83) 1
n/a n/a n/a 1.15 (1.04–
1.28) 5
1.36 (1.14–
1.62) 4
1.54 (1.30–
1.83) 4
TNF-blocker vs. control (Estabilished and late RA, disease duration .2 years)
Infliximab 2.44 (1.41–
4.20) 1
3.88 (1.46–
10.31) 1
12.83 (0.78–
211.37) 1
1.89 (1.00–
3.56) 2
3.08 (0.91–
10.43) 2
5.17 (0.61–
43.54) 2
3.17 (2.05–
4.89) 1
4.27 (2.18–
8.38) 1
9.19 (2.30–
36.73) 1
Etanercept 2.07 (1.25–
3.42) 5
3.96 (1.55–
10.14) 5
3.14 (1.93–
5.10) 5
3.72 (1.91–
7.24) 2
8.61 (3.55–
20.86) 2
11.40 (2.21–
58.65) 2
1.07 (0.98–
1.17) 1
1.36 (1.15–
1.61) 1
1.79 (1.33–
2.41) 1
Adalimumab 3.40 (1.79–
6.48) 3
5.42 (1.75–
16.80) 3
8.25 (2.33–
29.19) 3
2.53 (1.87–
3.43) 5
4.34 (3.30–
5.70) 5
5.44 (3.03–
9.76) 5
2.46 (1.87–
3.22) 1
4.37 (2.77–
6.91) 1
5.15 (2.60–
10.22) 1
Golimumab 1.56 (1.24–
1.97) 2
3.03 (1.82–
5.04) 2
2.91 (1.21–
7.00) 2
1.42 (0.95–
2.12) 2
1.56 (0.93–
2.60) 2
1.72 (0.74–
3.99) 2
n/a n/a n/a
Certolizumab n/a n/a n/a 3.67 (1.35–
9.96) 3
5.95 (3.97–
8.92) 3
8.12 (3.96–
16.63) 3
n/a n/a n/a
Combined 2.22 (1.60–
3.07) 11
4.01 (2.34–
6.87) 11
3.50 (2.35–
5.21) 11
2.50 (1.90–
3.30) 14
4.07 (2.70–
6.13) 14
4.94 (2.80–
8,71) 14
2.00 (0.83–
4.81) 3
2.86 (1.07–
7.65) 3
3.84 (1.39–
10.61) 3
Bolded risk ratios highlight statistically significant results (P,0.05), TNF = Tumour Necrosis Factor.
Superscript indicates the number of RCTs included in the comparison, RA = Rheumatoid Arthritis.
doi:10.1371/journal.pone.0030275.t002
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Table 3. Meta-analysis of the efficacy of combination TNF-blocker and MTX compared to MTX (RR, 95% CI).
TNF-blocker + MTX vs. MTX (both MTX naive patients and patients with previous experience with MTX)
Infliximab 2.51 (1.51–
4.15) 2
4.44 (1.77–
11.16) 2
12.92 (1.81–
92.02) 2
1.89 (1.00–
3.56) 2
3.08 (0.91–
10.43) 2
5.17 (0.61–
43.54) 2
1.70 (0.86–
3.38) 3
2.24 (1.11–
4.50) 3
2.71 (1.09–
6.70) 3
Etanercept 1.77 (1.06–
2.96) 3
4.40 (0.98–
19.73) 3
4.24 (2.43–
7.40) 3
2.67 (1.44–
4.94) 1
11.69 (1.66–
82.47) 1
9.82 (0.59–
163.15) 1
1.20 (1.06–
1.36) 2
1.51 (1.35–
1.69) 2
1.93 (1.46–
2.56) 2
Adalimumab 1.63 (0.69–
3.83) 1
2.06 (0.54–
7.90) 1
3.97 (0.24–
66.96) 1
2.38 (1.52–
3.72) 3
3.16 (1.29–
7.69) 3
4.82 (2.43–
9.57) 3
1.67 (0.76–
3.68) 2
2.39 (0.70–
8.16) 2
2.78 (0.87–
8.85) 2
Golimumab 1.67 (1.32–
2.12) 2
3.52 (2.10–
5.90) 2
3.36 (1.36–
8.29) 2
1.61 (0.94–
2.76) 2
1.78 (0.91–
3.48) 2
1.98 (0.82–
4.77) 2
n/a n/a n/a
Certolizumab n/a n/a n/a 5.08 (3.46–
7.48) 2
6.43 (3.33–
12.44) 2
7.87 (3.75–
16.51) 2
n/a n/a n/a
Combined 1.78 (1.38–
2.30) 8
3.54 (1.97–
6.34) 8
4.23 (2.69–
6.67) 8
2.48 (1.76–
3.49) 10
3.37 (2.09–
5.44) 10
4.23 (2.35–
7.60) 10
1.45 (1.20–
1.74) 7
1.84 (1.46–
2.31) 7
2.10 (1.62–
2.71) 7
TNF-blocker + MTX vs. MTX (patients with previous experience with MTX)
Infliximab 2.44 (1.41–
4.20) 1
3.88 (1.46–
10.31) 1
12.83 (0.78–
211.37) 1
1.89 (1.00–
3.56) 2
3.08 (0.91–
10.43) 2
5.17 (0.61–
43.54) 2
3.17 (2.05–
4.89) 1
4.27 (2.18–
8.38) 1
9.19 (2.30–
36.73) 1
Etanercept 1.77 (1.06–
2.96) 3
4.40 (0.98–
19.73) 3
4.24 (2.43–
7.40) 3
2.67 (1.44–
4.94) 1
11.69 (1.66–
82.47) 1
9.82 (0.59–
163.15) 1
1.13 (1.03–
1.24) 1
1.60 (1.35–
1.90) 1
2.27 (1.67–
3.09) 1
Adalimumab 1.63 (0.69–
3.83) 1
2.06 (0.54–
7.90) 1
3.97 (0.24–
66.96) 1
2.38 (1.52–
3.72) 3
3.16 (1.29–
7.69) 3
4.82 (2.43–
9.57) 3
2.46 (1.87–
3.22) 1
4.37 (2.77–
6.91) 1
5.15 (2.60–
10.22) 1
Golimumab 1.67 (1.32–
2.12) 2
3.52 (2.10–
5.90) 2
3.36 (1.36–
8.29) 2
2.14 (1.59–
2.89) 1
2.57 (1.60–
4.14) 1
3.31 (1.50–
7.28) 1
n/a n/a n/a
Certolizumab n/a n/a n/a 5.08 (3.46–
7.48) 2
6.43 (3.33–
12.44) 2
7.87 (3.75–
16.51) 2
n/a n/a n/a
Combined 1.75 (1.35–
2.27) 7
3.34 (1.86–
6.00) 7
4.10 (2.59–
6.51) 7
2.69 (1.93–
3.75) 9
3.37 (2.38–
5.98) 9
4.70 (3.07–
7.19) 9
2.04 (0.85–
4.86) 3
3.01 (1.26–
7.21) 3
4.05 (1.76–
9.32) 3
TNF-blocker + MTX vs. MTX (MTX naive patients exclusively)
Infliximab 3.00 (0.79–
11.44) 1
13.00 (0.83–
203.83) 1
13.00 (0.83–
203.83) 1
n/a n/a n/a 1.20 (1.07–
1.36) 2
1.52 (1.26–
1.82) 2
1.68 (1.32–
2.14) 2
Etanercept n/a n/a n/a n/a n/a n/a 1.28 (1.16–
1.42) 1
1.44 (1.24–
1.68) 1
1.71 (1.35–
2.16) 1
Adalimumab n/a n/a n/a n/a n/a n/a 1.16 (1.03–
1.31) 1
1.35 (1.15–
1.59) 1
1.64 (1.29–
1.92) 1
Golimumab n/a n/a n/a 1.25 (1.04–
1.49) 1
1.31 (0.99–
1.72) 1
1.35 (0.89–
2.05) 1
n/a n/a n/a
Certolizumab n/a n/a n/a n/a n/a n/a n/a n/a n/a
Combined 3.00 (0.79–
11.44) 1
13.00 (0.83–
203.83) 1
13.00 (0.83–
203.83) 1
1.25 (1.04–
1.49) 1
1.31 (0.99–
1.72) 1
1.35 (0.89–
2.05) 1
1.22 (1.14–
1.30) 4
1.43 (1.30–
1.57) 4
1.67 (1.46–
1.92) 4
Bolded risk ratios highlight statistically significant results (P,0.05), RA = Rheumatoid Arthritis, MTX=Methotrexate.
Superscript indicates the number of RCTs included in the comparison, TNF = Tumour Necrosis Factor.
doi:10.1371/journal.pone.0030275.t003
Table 4. Meta-analysis of the efficacy of combination TNF-blocker and MTX compared to TNF-blocker monotherapy (RR, 95% CI).
TNF-blocker + MTX vs. TNF-blocker
Infliximab n/a n/a n/a n/a n/a n/a n/a n/a n/a
Etanercept 1.14 (1.01–
1.29) 1
1.27 (1.00–
1.62) 1
2.34 (1.46–
3.77) 1
n/a n/a n/a 1.12 (1.02–
1.23) 1
1.43 (1.22–
1.69) 1
1.77 (1.34–
2.33) 1
Adalimumab n/a n/a n/a n/a n/a n/a 1.35 (1.19–
1.54) 1
1.52 (1.28–
1.80) 1
1.77 (1.40–
2.25) 1
Golimumab 1.25 (0.99–
1.58) 1
1.58 (1.06–
2.35) 1
1.49 (0.72–
3.09) 1
1.40 (1.00–
1.96) 2
1.41 (0.94–
2.11) 2
1.53 (1.08–
2.17) 2
n/a n/a n/a
Certolizumab n/a n/a n/a n/a n/a n/a n/a n/a n/a
Combined 1.16 (1.05–
1.29) 2
1.35 (1.09–
1.66) 2
2.04 (1.36–
3.07) 2
1.40 (1.00–
1.96) 2
1.41 (0.94–
2.11) 2
1.53 (1.08–
2.17) 2
1.22 (1.01–
1.49) 1
1.47 (1.31–
1.66) 1
1.77 (1.48–
2.12) 1
Bolded risk ratios highlight statistically significant results (P,0.05), RA = Rheumatoid Arthritis, MTX=Methotrexate.
Superscript indicates the number of RCTs included in the comparison, TNF = Tumour Necrosis Factor.
doi:10.1371/journal.pone.0030275.t004
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To investigate the possible effect of study patients’ baseline
disease activity on efficacy, two additional analyses were
performed. Using ACR 50 at six months as outcome and
stratifying trials into two categories by the number of swollen
joints or Health Assessment Questionnaire (HAQ) score revealed
no statistical differences between the subgroups. Trials with low
swollen joint count and low HAQ score had risk ratios of 3.43 (CI
95% 2.03–5.78) and 3.68 (2.11–6.42), respectively, whereas trials
with high swollen joint count and high HAQ score had risk ratios
of 5.15 (2.72–9.75) and 4.64 (2.59–8.31), respectively.
Safety
TNF-blocker vs. control. The primary safety endpoint of
the systematic review was the discontinuation of study due to
adverse events. There were 25 studies with 6292 patients in the
intervention and 2994 in the control group in this analysis (table 6).
As a group, the TNF-blockers did not statistically significantly
differ from the control (RR 1.26, CI 95% 0.93–1.71). While the
patients on infliximab (3.22, 1.76–5.91), adalimumab (1.59, 1.13–
2.23), and certolizumab (2.72, 1.23–6.01), had an increased risk to
discontinue, the patients on etanercept (0.71, 0.54–0.92) had a
decreased risk (figure 3). Patients using certolizumab had a higher
risk to experience a serious adverse event than patients on
etanercept with risk ratios of 2.24 (1.38–3.63) and 0.90 (0.68–
1.20), respectively. Infliximab, etanercept and golimumab
increased the likelihood of an injection or infusion reaction while
adalimumab and certolizumab did not statistically significantly
differ from the controls in this respect although their risk ratios
leaned to the same direction.
TNF-blocker + MTX vs. MTX. In this comparison,
etanercept no longer significantly decreased the likelihood of
discontinuation due to adverse event (RR 0.78, CI 95% 0.56–
1.09). Combined results from all substances now reached statistical
significance (1.37, 1.01–1.87). In an analysis comparing the
combination treatment to monotherapy there were only few
differences between treatment groups. There was a trend of
elevated risk ratios of multiple safety endpoints excluding injection
reactions but these findings did not reach statistical significance.
Golimumab increased the odds for an unspecified adverse event
(1.14, 1.03–1.26) while others did not.
TNF-blocker monotherapy vs. MTX. TNF-blocker and
MTX were comparable in all respects other than injection and
infusion reactions (RR 5.20, CI 95% 2.62–10.31).
TNF-blocker monotherapy vs. placebo. The comparison
of TNF-blockers and placebo showed a trend of increased risk of
adverse events from TNF-blockers, but only the increase in the
frequency of injection reactions was statistically significant (RR
3.69, CI 95% 1.03–13.23). In addition, certolizumab seemed to
increase the risk to experience an adverse event compared to
placebo (1.31, 1.08–1.26).
High doses of TNF-blockers vs. normal doses. Increased
dose of the TNF-blockers did not increase the frequency of
discontinuations due to adverse events (RR 0.98, CI 95% 0.72–
1.35), but the likelihood to experience an unspecified adverse event
was reduced compared to normal doses (0.93, 0.89–0.97). Patients
on high doses of infliximab were less likely to suffer from infusion
reactions compared to those on regular doses (0.73, 0.56–0.94).
Discussion
Findings of this review
Our systematic literature search identified 40 publications
reporting 26 randomized controlled trials studying the efficacy
and safety of TNF-blockers. The included trials were published
1999–2010. Five trials published used infliximab [49–59], seven
etanercept [60–72], eight adalimumab [73–82], three golimumab
[83–85] and three certolizumab [86–88] for the intervention.
Overall, there were 6780 patients in the intervention and 3082 in
the control group. The patients’ characteristics varied across the
included trials with mean time since diagnosis ranging from 0.5 to
13 years, HAQ score from 1.25 to 1.88 and the number of swollen
and tender joints from 11 and 14.03 to 24 and 37.2, respectively.
The results of the primary efficacy endpoint suggest that
infliximab and golimumab do not statistically significantly differ
from control regarding efficacy in a comparison between any
combination of TNF-blocker and any control. Even though the
different settings and heterogeneity among the studies could have
accounted for the result, the finding still raises questions.
Golimumab appears to be inferior in efficacy to etanercept,
adalimumab and certolizumab even after accounting for the
eventual bias. Patients in golimumab trials have lower count of
swollen and tender joints as well as lower HAQ score, which may
explain the results to some extent, although an ad hoc analysis on
the effect of patient characteristics on efficacy showed no statistical
significance. Disease duration seems to predict treatment response
to adalimumab and infliximab at 12 months.
Table 5. Meta-analysis of the efficacy of high doses of TNF-blockers compared to normal doses of TNF-blockers.
High doses of TNF-blocker vs. normal doses (both high and normal dose of TNF-blocker in combination with MTX or vice versa)
Infliximab 0.86 (0.61–
1.22) 1
1.15 (0.66–
2.02) 1
0.96 (0.30–
3.11) 1
1.07 (0.84–
1.36) 1
1.09 (0.72–
1.63) 1
1.57 (0.72–
3.40) 1
1.16 (0.93–
1.46) 2
1.36 (0.84–
2.19) 2
1.43 (0.81–
2.52) 2
Etanercept n/a n/a n/a n/a n/a n/a n/a n/a n/a
Adalimumab 1.26 (0.93–
1.71) 1
1.27 (0.74–
2.16) 1
0.70 (0.33–
1.47) 1
1.08 (0.92–
1.26) 3
1.12 (0.71–
1.76) 3
1.08 (0.68–
1.70) 3
n/a n/a n/a
Golimumab 1.02 (0.84–
1.25) 2
0.81 (0.58–
1.13) 2
0.93 (0.40–
2.15) 2
1.00 (0.87–
1.15) 2
0.90 (0.71–
1.13) 2
0.75 (0.52–
1.07) 2
n/a n/a n/a
Certolizumab n/a n/a n/a 1.02 (0.93–
1.12) 2
1.06 (0.91–
1.22) 2
0.84 (0.60–
1.19) 2
n/a n/a n/a
Combined 1.04 (0.90–
1.21) 4
0.96 (0.75–
1.24) 4
0.82 (0.52–
1.31) 4
1.03 (0.97–
1.10) 8
1.02 (0.90–
1.15) 8
0.91 (0.74–
1.10) 8
1.16 (0.93–
1.46) 2
1.36 (0.84–
2.19) 2
1.43 (0.81–
2.52) 2
Bolded risk ratios highlight statistically significant results (P,0.05), RA = Rheumatoid Arthritis, MTX=Methotrexate.
Superscript indicates the number of RCTs included in the comparison, TNF = Tumour Necrosis Factor.
doi:10.1371/journal.pone.0030275.t005
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In the second and third meta-analysis the efficacy of MTX and
TNF-blocker combination was found to be superior to either
MTX or TNF-blocker alone, respectively. The increase in the
number of discontinuations due to adverse events (RR 1.37 95%
1.01–1.87) compared to MTX alone is likely to be acceptable.
Patients with previous exposure to MTX were more likely to
benefit from the combination therapy compared to MTX naı¨ve
patients. Compared to monotherapy with a TNF-blocker the
Table 6. Meta-analysis of the safety of TNF-blockers in different comparisons (RR, 95% CI).
Discontinuation due
to adverse event
All adverse
events
Serious adverse
events
All
infections
Serious
infections
Injection or infusion
reactions
TNF-blocker vs. control
Infliximab 3.22 (1.76–5.91)4 1.02 (0.93–1.13)2 1.01 (0.70–1.47)4 1.51 (0.92–2.47)3 1.45 (0.63–3.35)3 1.76 (1.03–3.03)3
Etanercept 0.71 (0.54–0.92)7 1.02 (0.97–1.07)1 0.90 (0.68–1.20)3 0.88 (0.65–1.20)2 0.87 (0.48–1.58)3 4.46 (3.13–6.36)5
Adalimumab 1.59 (1.13–2.23)8 1.04 (0.94– 1.15)4 1.03 (0.71–1.49)5 1.34 (0.93–1.94)4 2.89 (0.68–12.36)4 3.08 (0.94–10.13)7
Golimumab 0.98 (0.46– 2.08)3 1.05 (0.97– 1.13)3 1.24 (0.57–2.73)3 1.03 (0.74–1.44)3 1.41 (0.53–3.72)3 2.20 (1.15–4.19)3
Certolizumab 2.72 (1.23–6.01)3 1.15 (0.89– 1.48)2 2.24 (1.38–3.63)3 0.62 (0.37–1.22)1 6.11 (0.78–47.93)2 1.53 (0.15–15.28)3
Combined 1.26 (0.93–1.71)24 1.04 (1.00–1.09)14 1.10 (0.91–1.34)18 1.10 (0.89–1.36)13 1.40 (0.93–2.10)15 2.46 (1.63–3.70)21
TNF-blocker + MTX vs. MTX
Infliximab 2.06 (1.05–4.07)5 1.02 (0.93–1.13)2 1.04 (0.65–1.66)4 1.23 (0.94–1.61)3 1.45 (0.63–3.35)3 1.76 (1.03–3.03)3
Etanercept 0.78 (0.56–1.09)4 0.99 (0.94–1.03)2 0.85 (0.62–1.16)3 0.97 (0.78–1.20)2 0.71 (0.37–1.36)3 4.44 (1.81–10.86)4
Adalimumab 1.58 (1.08–2.33)5 1.02 (0.99–1.06)3 1.23 (0.49–3.10)2 1.20 (0.85–1.71)3 2.37 (0.38–14.91)3 1.04 (0.51–2.11)4
Golimumab 1.20 (0.48–3.00)3 1.08 (1.00–1.18)3 1.45 (0.66–3.16)3 0.99 (0.79–1.24)3 1.59 (0.60–4.26)3 2.15 (1.11–4.15)3
Certolizumab 2.82 (1.14–6.98)2 1.01 (0.84–1.22)1 2.18 (1.30–3.67)2 1.19 (0.82–1.73)1 7.38 (0.44–122.91)1 5.31 (0.72–39.41)2
Combined 1.37 (1.01–1.87)19 1.02 (0.99–1.04)11 1.14 (0.89–1.47)14 1.08 (0.97–1.20)12 1.28 (0.81–2.04)13 2.08 (1.40–3.10)16
TNF-blocker + MTX vs. TNF-blocker
Infliximab n/a n/a n/a n/a n/a n/a
Etanercept 0.93 (0.55–1.57)1 0.94 (0.87–1.02)1 0.80 (0.51–1.26)1 1.13 (0.98–1.31)1 0.97 (0.41–11.21)1 0.48 (0.30–0.77)1
Adalimumab 1.26 (0.77–2.05)2 1.02 (0.99.1.05)1 n/a n/a 3.07 (0.84–11.21)1 n/a
Golimumab 2.45 (0.46–12.93)1 1.14 (1.03–1.26)2 1.97 (0.98–3.95)2 0.94 (0.76–1.16)2 3.02 (0.88–10.30)2 0.83 (0.37–1.87)2
Certolizumab n/a n/a n/a n/a n/a n/a
Combined 1.19 (0.78–1.80)4 1.04 (0.96–1.13)4 1.29 (0.65–2.58)3 1.06 (0.93–1.21)3 1.83 (0.88–3.81)4 0.62 (0.38–1.00)3
TNF-blocker vs. MTX
Infliximab n/a n/a n/a n/a n/a n/a
Etanercept 0.66 (0.40–1.07)2 1.06 (0.98–1.15)1 0.97 (0.63–1.48)1 0.91 (0.79–1.05)1 1.02 (0.43–2.41)1 6.89 (3.05–8.35)2
Adalimumab 1.28 (0.73–2.26)1 1.00 (0.97–1.04)1 n/a n/a 0.40 (0.11–1.54)1 n/a
Golimumab 0.67 (0.19–2.36)2 0.97 (0.86–1.08)2 0.80 (0.23–2.79)2 1.13 (0.89–1.44)2 0.75 (0.17–3.36)2 2.94 (0.70–12.30)2
Certolizumab n/a n/a n/a n/a n/a n/a
Combined 0.81 (0.56–1.18)5 1.01 (0.98–1.04)4 0.89 (0.53–1.47)3 1.00 (0.84–1.19)3 0.78 (0.40–1.49)4 5.20 (2.62–10.31)4
TNF-blocker vs. placebo
Infliximab n/a n/a n/a n/a n/a n/a
Etanercept 0.68 (0.12–3.98)1 n/a n/a n/a n/a 3.90 (2.09–7.27)1
Adalimumab 2.27 (0.95–5.40)3 1.06 (0.98–1.14)1 0.99 (0.66–1.50)3 1.19 (0.86–1.64)1 4.15 (0.78–22.18)2 7.71 (3.39–17.54)3
Golimumab n/a n/a n/a n/a n/a n/a
Certolizumab 2.45 (0.49–12.39)1 1.31 (1.08–1.59)1 2.62 (0.71–9.61)1 n/a 4.91 (0.24–101.13)1 0.33 (0.12–0.87)1
Combined 1.90 (0.94–3.84)5 1.16 (0.88–1.53)2 1.13 (0.71–1.80)4 1.19 (0.86–1.64)1 4.32 (1.00–18.70)3 3.69 (1.03–13.23)5
High doses of TNF-blocker vs. normal doses
Infliximab 1.14 (0.76–1.73)3 0.99 (0.78–1.25)1 1.19 (0.65–2.17)3 0.92 (0.53–1.59)2 1.49 (0.33–6.67)2 0.73 (0.56–0.94)2
Etanercept n/a n/a n/a n/a n/a n/a
Adalimumab 0.43 (0.17–1.05)3 0.94 (0.89–1.00)1 0.87 (0.45–1.71)3 0.94 (0.68–1.32)1 0.52 (0.13–2.03)1 1.31 (0.79–2.17)4
Golimumab 1.19 (0.54–2.61)3 0.92 (0.82–1.02)3 1.04 (0.58–1.85)3 0.90 (0.71–1.14)3 2.28 (0.83–6.27)3 1.52 (0.86–2.69)3
Certolizumab 0.87 (0.34–2.20)2 0.91 (0.77–1.07)1 1.06 (0.76–1.46)2 0.77 (0.57–1.06)1 0.76 (0.27–2.15)1 0.73 (0.15–3.52)2
Combined 0.98 (0.72–1.35)11 0.93 (0.89–0.97)6 1.01 (0.83–1.23)11 0.92 (0.79–1.07)7 1.10 (0.66–1.87)7 1.05 (0.78–1.40)11
Bolded risk ratios highlight statistically significant results (P,0.05), RA = Rheumatoid Arthritis, MTX=Methotrexate.
Superscript indicates the number of RCTs included in the comparison, TNF = Tumour Necrosis Factor.
doi:10.1371/journal.pone.0030275.t006
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Figure 3. Forest plot of the number of discontinuations due to an adverse event.
doi:10.1371/journal.pone.0030275.g003
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safety of the combination treatment was equal or even improved
regarding some aspects.
The fourth meta-analysis found no statistical difference between
MTX and TNF-blocker monotherapy and the fifth one confirmed
that TNF-blocker monotherapy was more efficacious than
placebo. The last secondary efficacy meta-analysis found little
benefit from increasing the dose of TNF-blockers.
In the first safety comparison between TNF-blockers and
control the risk ratios reached statistical significance only in the
number of patients experiencing injection or infusion reactions.
Interestingly, infliximab, adalimumab and certolizumab increased
the risk of discontinuation of treatment due to adverse events, but
etanercept made it less likely. Certolizumab was the only TNF-
blocker which increased the likelihood of experiencing a serious
adverse event. While TNF-blockers as a group increased the odds
to experience an injection or infusion reaction this may not be the
case with adalimumab and certolizumab.
Strengths and limitations
It could be asked, whether TNF-blocker naive and switchers
should be included in the same review, because these patients
could be very different. However, fifteen trials included in this
systematic review stated previous TNF-blocker use as an exclusion
criterion. In eight more trials it was unclear if switchers were
included and only two certolizumab trials included switchers but
excluded those who had had insufficient response to previous
TNF-blocker treatment. However, the percentage of previous
TNF-blocker users in these two trials was small (2–4%) and a
sensitivity analysis was performed.
While broader comparisons with larger number of trials may be
more likely to reach statistically significant results (1.00 not
included in the confidence interval), their validity may be
questioned. Heterogeneity introduced by combining the results
of trials with different settings causes random effects model to
calculate wider confidence intervals than fixed effects model would
do. While reducing the possibility of type I error, it may introduce
a type II error. Hence, the efficacies of TNF-blockers were
compared with different controls, combinations and dosages in
smaller, but more homogenous comparisons.
Results of the sensitivity analyses revealed that the source of bias
in the RCTs is as likely to lead to underestimation as
overestimation of the risk difference between intervention and
control groups. However, the homogeneity of study population,
intervention, control, outcomes and study settings are likely to be
more crucial to the validity of the meta-analysis. Length of
exposure was not taken into account in the safety analyses, only
the difference in risk ratios between intervention and control
group.
The methods used in the study were derived from the
Handbook for systematic reviews of interventions by Cochrane
Collaboration. The team involved in study design and execution
included clinicians, methodology experts and pharmacists. Two
researchers independently worked at each step and afterwards
combined their results to improve the validity of the study. The
meta-analyses were done using Review Manager 5.0 –software.
The report was written in accordance to the PRISMA-statement
(table S3).
Our systematic review and meta-analysis has some limitations.
The authors of the included trials were not contacted to retrieve
unpublished data. Many studies that lasted for one year or more
only reported results at 12 months. The meta-analyses would have
been more powered if the efficacy results had been reported at all
time points. Selective reporting was included in the evaluation for
bias, but we were unable to identify any bias here.
Findings in comparison to other systematic reviews
Another systematic review and meta-analysis pooled efficacy
results from different time points and found slightly different
estimates for the efficacy of TNF-blockers, which is likely due to
differences in study designs [12]. Several large clinical trials have
been published since the aforementioned review along with the
introduction of two novel TNF-blockers, certolizumab and
golimumab. Our study distinguishes itself from previous systematic
reviews by including larger number of clinical trials and by
presenting efficacy results separately at three, six and twelve
months. Our results reveal that the new substances do not offer
improved efficacy or safety profile over the already existing ones. A
recent systematic review concluded that certolizumab is at least as
efficacious compared to older TNF-blockers [14]. However, the
study did not include studies with MTX comparison nor evaluate
the safety of biologic treatments. Certolizumab may be more
efficacious than golimumab but may also be associated with a
greater risk of serious adverse events.
A previous systematic review reached the same conclusion as we
did, regarding the increased dose of TNF-blockers. Contradicting
our results, they found high doses leading to two-fold risk of serious
infections. In contrast to our direct approach, they however
separately compared recommended and high doses of TNF-
blockers to placebo [10]. Another systematic review concluded
that infliximab might require an increased dosage level to reach
similar efficacy as etanercept and adalimumab have [13].
Implications for practise and research
The novel TNF-blockers may offer an alternative to older
substances but do not make them obsolete. On the contrary,
etanercept may be the best choice when taking into account safety
profiles of the TNF-blockers. Infliximab, etanercept and adalimu-
mab have been in clinical use for years with extensive amount of
post-marketing data available. More post-marketing information is
needed on certolizumab and golimumab for comprehensive
pharmacovigilance.
The annual medication costs of TNF-blockers are more than
10 000J while the MTX treatment costs less than 100J per year.
Subgroup analysis in table 3 suggests that considering the high
expenses of biologics, the treatment of RA could be initiated with
MTX while combining TNF-blockers to ongoing treatment in
patients with insufficient response to MTX. Even though safety
was not compromised, it might not be cost-effective to use high
doses of TNF-blockers. Given the limited resources in healthcare
systems our results may help clinicians and decision makers to get
most out of the expensive, but efficacious treatment.
The next step could be to analyze the efficacy and safety of not just
TNF-blockers, but all biologics in a large systematic review and meta-
analysis. One randomized clinical trial included in our systematic
review actually compared abatacept to infliximab [55]. However, a
systematic review is indicated to summarise the evidence.
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